VOTRIENT (pazopanib) 200mg, 400mg tablets by GlaxoSmithKline
The FDA has approved Votrient (pazopanib tablets, from GlaxoSmithKline), an angiogenesis inhibitor, for the treatment of advanced renal cell carcinoma (RCC). This approval was based on results from a Phase 3 clinical trial which showed that Votrient reduced the risk of tumor progression or death by 54% compared to placebo, regardless of prior treatment. Overall median progression-free survival (PFS) was 9.2 months with Votrient and 4.2 months with placebo. Treatment-naive patients who received Votrient experienced 11.1 months of median PFS versus 2.8 months with placebo. Additionally, patients who had previously received cytokine-based treatment achieved 7.4 months of median PFS with Votrient compared to 4.2 months with placebo.
Votrient is expected to be available in mid-November 2009.
For more information call (888) 825-5249 or visit www.gsk.com.